Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($1.03), $0.20 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $7.89 million versus the consensus estimate of $16.05 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.